ScreenerHero

AGMB AgomAb Therapeutics NV

NAS · US · Healthcare · Biotechnology · agomab.com
9.220USD+4.77%Mkt Cap: 454.07M $P/E: —

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontuni…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.47BUSDP/E 29.3
MRNA
Moderna, Inc.
$78.65BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.14BUSDP/E 18.3
ARGX
argenx SE
$51.48BUSDP/E 31.2
ARGX
argenx SE
$48.23BUSDP/E 31.4
UCB
UCB SA
$41.82BUSDP/E 17.8
RVMD
Revolution Medicines, Inc.
$40.32BUSD
ONC
BeOne Medicines AG
$39.83BUSDP/E 62.6
RPRX
Royalty Pharma plc
$32.48BUSDP/E 29.9
ALNY
Alnylam Pharmaceuticals, Inc.
$30.04BUSDP/E 37.9
ROIV
Roivant Sciences Ltd.
$24.71BUSD
BNTX
BioNTech SE
$23.13BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
GMAB
Genmab A/S
$22.17BUSDP/E 28.4
INSM
Insmed Incorporated
$21.94BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$14.65BUSDP/E 17.1
EXEL
Exelixis, Inc.
$14.62BUSDP/E 18.6
JAZZ
Jazz Pharmaceuticals plc
$14.44BUSDP/E 15.2
SMMT
Summit Therapeutics Inc.
$13.70BUSD

Key Statistics

Company
Market Cap454.07M USD
Enterprise Value282.46M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-62.55M USD
Revenue/Share—
Last Price9.220 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees62
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.32
PEG—
EV/EBITDA-4.31
EV/Revenue—
P/S—
P/B3.46
EPS (TTM)-2.08
EPS (Forward)-2.05
52W Range
7.97013% of range17.82
52W High17.82 USD
52W Low7.970 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-47.78%
ROA-40.69%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-51.74M USD
CapEx (TTM)4.00K USD
FCF Margin—
FCF Yield—
Net Debt-250.84M USD
Net Debt/EBITDA3.83
Balance Sheet
Debt/Equity0.01
Current Ratio12.88
Quick Ratio12.55
Book Value/Sh2.55 USD
Cash/Share6.18 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)37.67 USD
Upside (mean)+308.5%
Target Range28.00 USD – 60.00 USD
28.00+308.5% to mean60.00
# Analysts6
Ownership
Shares Out.49.25M
Float11.45M
Insiders5.90%
Institutions53.72%
Short Interest
Short Ratio5.4d
Short % Float2.13%
Short % Out.1.76%
Shares Short867.70K
Short (prev mo.)941.12K
Technical
SMA 5012.83 (-28.1%)
SMA 20012.50 (-26.3%)
Beta—
S&P 52W Chg16.45%
Avg Vol (30d)181.86K
Avg Vol (10d)192.82K
Technical Indicators
RSI (14)35.6
MACD-1.1490
MACD Signal-1.0014
MACD Hist.-0.1476
BB Upper13.50 USD
BB Middle10.64 USD
BB Lower7.779 USD
BB Width53.78%
ATR (14)1.045 USD
Vol Ratio (20d)1.35x